See more : Avecho Biotechnology Limited (AVEFF) Income Statement Analysis – Financial Results
Complete financial analysis of Timber Pharmaceuticals, Inc. (TMBR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Timber Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Reconnaissance Energy Africa Ltd. (RECO.V) Income Statement Analysis – Financial Results
- Pyramid AG (M3BK.DE) Income Statement Analysis – Financial Results
- Capital Group Holdings, Inc. (CGHC) Income Statement Analysis – Financial Results
- Electreon Wireless Ltd (ELWSF) Income Statement Analysis – Financial Results
- Pyrum Innovations AG (PYRUM.OL) Income Statement Analysis – Financial Results
Timber Pharmaceuticals, Inc. (TMBR)
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.18K | 295.74K | 453.81K | 324.65K | 57.00K | 73.00K | 100.00K | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.30M | 6.15M | 1.50M | 3.38M | 83.00K | 250.00K | 516.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.22M | -5.85M | -1.05M | -3.06M | -26.00K | -177.00K | -416.00K | -173.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -15,892.35% | -1,979.40% | -230.78% | -941.95% | -45.61% | -242.47% | -416.00% | -270.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.30M | 6.15M | 15.10M | 3.38M | 9.08M | 9.14M | 10.16M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 5.24M | 5.14M | 4.65M | 4.17M | 0.00 | 52.31K | 27.96K | 59.11K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.16M | 2.42M | 3.20M | 5.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 5.39M | 4.06M | 586.56K | 7.40M | 7.56M | 7.85M | 9.28M | 0.00 | 52.31K | 27.96K | 59.11K |
| Other Expenses | -83.18K | -590.79K | -453.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.24M | 10.95M | 18.71M | 586.72K | 16.48M | 16.70M | 18.01M | 14.99M | 0.00 | 52.31K | 27.96K | 59.11K |
| Cost & Expenses | 19.24M | 10.95M | 18.71M | 3.97M | 16.56M | 16.95M | 18.53M | 15.22M | 0.00 | 52.31K | 27.96K | 59.11K |
| Interest Income | 2.45K | 15.55K | 816.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 0.00 |
| Interest Expense | 228.46K | 15.55K | 4.42M | 0.00 | 28.00K | 364.00K | 163.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 77.45K | 272.88K | 2.43M | 171.86K | 62.00K | 52.00K | 260.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.16M | -10.38M | -17.78M | -45.56K | -17.17M | -16.88M | -17.98M | -15.16M | 0.00 | -52.31K | -27.96K | -59.11K |
| EBITDA Ratio | -23,032.75% | -3,601.23% | -3,917.31% | -14.03% | -30,115.79% | -32,717.81% | -17,981.00% | -24,231.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.24M | -10.65M | -20.21M | -3.64M | -17.23M | -23.94M | -18.24M | -15.59M | 0.00 | -52.31K | -27.96K | -59.11K |
| Operating Income Ratio | -23,125.86% | -3,601.23% | -4,453.82% | -1,122.63% | -30,224.56% | -32,789.04% | -18,241.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -136.45K | -19.17K | 5.13M | -156.00 | -750.00K | 238.00K | -163.00K | -436.00K | 0.00 | 1.00 | 2.00 | 0.00 |
| Income Before Tax | -19.37M | -10.67M | -15.08M | -3.64M | -17.26M | -16.64M | -18.40M | -15.59M | 0.00 | -52.30K | -27.96K | -59.11K |
| Income Before Tax Ratio | -23,289.91% | -3,607.72% | -3,322.93% | -1,122.68% | -30,273.68% | -22,791.78% | -18,404.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 7.60K | -30.24K | 37.84K | -156.00 | 2.00K | -7.66M | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -19.38M | -10.64M | -15.12M | -3.69M | -17.26M | -8.98M | -18.41M | -15.60M | 0.00 | -52.30K | -27.96K | -59.11K |
| Net Income Ratio | -23,299.05% | -3,597.49% | -3,331.27% | -1,136.66% | -30,277.19% | -12,298.63% | -18,406.00% | -24,371.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
| Weighted Avg Shares Out (Dil) | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
7 Reddit Penny Stocks to Watch for Big Upside Ahead
Timber Pharmaceuticals Announces Adjournment of Annual Meeting
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
Investing in Penny Stocks? Don't Before You Do These 3 Things
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results
7 Reddit Penny Stocks to Buy for a Biotech Boom
5 Reddit Penny Stocks Seeing the Most Chatter Thursday
DISCB and 6 Other Reddit Stocks Waiting for a Short Squeeze
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
Timber Pharmaceuticals Provides Business Update and Announces Year End 2020 Financial Results
Source: https://incomestatements.info
Category: Stock Reports